观察哌甲酯对儿童和青少年ASD-ADHD双重诊断的行为影响:一个小回顾。

Frontiers in child and adolescent psychiatry Pub Date : 2023-03-17 eCollection Date: 2023-01-01 DOI:10.3389/frcha.2023.1052115
Danilo Dimitri, Giuliana Delia, Maurizio Arduino, Nazarena Turco, Franco Fioretto
{"title":"观察哌甲酯对儿童和青少年ASD-ADHD双重诊断的行为影响:一个小回顾。","authors":"Danilo Dimitri, Giuliana Delia, Maurizio Arduino, Nazarena Turco, Franco Fioretto","doi":"10.3389/frcha.2023.1052115","DOIUrl":null,"url":null,"abstract":"<p><strong>Research aim: </strong>The aim of this study is to focus on the main neurophysiological aspects of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) and the current pharmacological treatment used for the management of hyperactivity and attention deficits in children aged 6-20 years with a diagnosis of ASD, not associated with other genetic or epileptic disorders, such as Fragile X Syndrome (FXS), Tuberous Sclerosis, Kleefstra Syndrome or Angelman Syndrome.</p><p><strong>Methods: </strong>This mini review was conducted according to the <i>P</i>.I.C.O. model and according to the PRISMA guidelines. The keywords used were: <i>autism spectrum disorder</i>; <i>attention deficit hyperactivity disorder</i>; <i>attention deficit disorder</i>; <i>methylphenidate</i>; <i>ritalin</i>; <i>ADHD</i>; <i>youth autism</i>; <i>childhood autism</i>; <i>childhood autism spectrum disorder</i>; <i>adolescent autism</i>. The strings produced were compared and selected by a third independent clinician. The PubMed and PsycArticles search yielded a total of 3,200 articles. For their inclusion, the 3,200 articles were examined by two clinicians who ultimately selected 28 (15 clinical trials and 13 reviews/meta-analyses) articles analysed according to their consistency with the inclusion and exclusion criteria.</p><p><strong>Conclusions: </strong>Three main aspects emerged from the review: (1) According to the existing literature, new randomized controlled trials are needed to ensure a better understanding of the most effective drug treatments for dual-diagnosed ASD-ADHD patients and of the related behavioural effects. Currently, the use of drugs varies depending on psychiatric comorbidity, symptoms, age and gender and there is no univocal reference therapy; (2) Methylphenidate (MPH) has currently been shown to be the most suitable drug for the treatment of hyperactivity and inattention in individuals diagnosed with ASD and ADHD; (3) There is a need to create and evaluate appropriate tests to analyse more specific patterns of behaviour presented in the two conditions.</p>","PeriodicalId":73074,"journal":{"name":"Frontiers in child and adolescent psychiatry","volume":"58 1","pages":"1052115"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732115/pdf/","citationCount":"0","resultStr":"{\"title\":\"Observing the behavioural effects of methylphenidate in children and adolescents with ASD-ADHD dual diagnosis: A mini review.\",\"authors\":\"Danilo Dimitri, Giuliana Delia, Maurizio Arduino, Nazarena Turco, Franco Fioretto\",\"doi\":\"10.3389/frcha.2023.1052115\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Research aim: </strong>The aim of this study is to focus on the main neurophysiological aspects of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) and the current pharmacological treatment used for the management of hyperactivity and attention deficits in children aged 6-20 years with a diagnosis of ASD, not associated with other genetic or epileptic disorders, such as Fragile X Syndrome (FXS), Tuberous Sclerosis, Kleefstra Syndrome or Angelman Syndrome.</p><p><strong>Methods: </strong>This mini review was conducted according to the <i>P</i>.I.C.O. model and according to the PRISMA guidelines. The keywords used were: <i>autism spectrum disorder</i>; <i>attention deficit hyperactivity disorder</i>; <i>attention deficit disorder</i>; <i>methylphenidate</i>; <i>ritalin</i>; <i>ADHD</i>; <i>youth autism</i>; <i>childhood autism</i>; <i>childhood autism spectrum disorder</i>; <i>adolescent autism</i>. The strings produced were compared and selected by a third independent clinician. The PubMed and PsycArticles search yielded a total of 3,200 articles. For their inclusion, the 3,200 articles were examined by two clinicians who ultimately selected 28 (15 clinical trials and 13 reviews/meta-analyses) articles analysed according to their consistency with the inclusion and exclusion criteria.</p><p><strong>Conclusions: </strong>Three main aspects emerged from the review: (1) According to the existing literature, new randomized controlled trials are needed to ensure a better understanding of the most effective drug treatments for dual-diagnosed ASD-ADHD patients and of the related behavioural effects. Currently, the use of drugs varies depending on psychiatric comorbidity, symptoms, age and gender and there is no univocal reference therapy; (2) Methylphenidate (MPH) has currently been shown to be the most suitable drug for the treatment of hyperactivity and inattention in individuals diagnosed with ASD and ADHD; (3) There is a need to create and evaluate appropriate tests to analyse more specific patterns of behaviour presented in the two conditions.</p>\",\"PeriodicalId\":73074,\"journal\":{\"name\":\"Frontiers in child and adolescent psychiatry\",\"volume\":\"58 1\",\"pages\":\"1052115\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732115/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in child and adolescent psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/frcha.2023.1052115\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in child and adolescent psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/frcha.2023.1052115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

研究目的:本研究的目的是关注注意力缺陷/多动障碍(ADHD)和自闭症谱系障碍(ASD)的主要神经生理学方面,以及目前用于管理6-20岁诊断为ASD的儿童多动和注意缺陷的药物治疗,这些儿童与其他遗传或癫痫性疾病(如脆性X综合征(FXS)、结节性硬化症、Kleefstra综合征或Angelman综合征)无关。方法:根据P.I.C.O.模型和PRISMA指南进行回顾性研究。使用的关键词是:自闭症谱系障碍;注意缺陷多动障碍;注意缺乏症;哌醋甲酯;利他林;多动症;青春自闭症;儿童孤独症;儿童自闭症谱系障碍;青少年自闭症。产生的字符串由第三个独立的临床医生进行比较和选择。PubMed和PsycArticles搜索总共产生了3200篇文章。为了纳入,两位临床医生对3200篇文章进行了检查,他们最终选择了28篇(15篇临床试验和13篇综述/荟萃分析)文章,根据它们与纳入和排除标准的一致性进行了分析。结论:综述总结了三个主要方面:(1)根据现有文献,需要开展新的随机对照试验,以确保更好地了解双重诊断的ASD-ADHD患者最有效的药物治疗方法及其相关的行为效应。目前,药物的使用因精神合并症、症状、年龄和性别而异,没有统一的参考治疗;(2)哌醋甲酯(MPH)目前已被证明是治疗ASD和ADHD患者多动和注意力不集中的最合适药物;(3)有必要建立和评价适当的测试,以分析在这两种情况下出现的更具体的行为模式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Observing the behavioural effects of methylphenidate in children and adolescents with ASD-ADHD dual diagnosis: A mini review.

Research aim: The aim of this study is to focus on the main neurophysiological aspects of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) and the current pharmacological treatment used for the management of hyperactivity and attention deficits in children aged 6-20 years with a diagnosis of ASD, not associated with other genetic or epileptic disorders, such as Fragile X Syndrome (FXS), Tuberous Sclerosis, Kleefstra Syndrome or Angelman Syndrome.

Methods: This mini review was conducted according to the P.I.C.O. model and according to the PRISMA guidelines. The keywords used were: autism spectrum disorder; attention deficit hyperactivity disorder; attention deficit disorder; methylphenidate; ritalin; ADHD; youth autism; childhood autism; childhood autism spectrum disorder; adolescent autism. The strings produced were compared and selected by a third independent clinician. The PubMed and PsycArticles search yielded a total of 3,200 articles. For their inclusion, the 3,200 articles were examined by two clinicians who ultimately selected 28 (15 clinical trials and 13 reviews/meta-analyses) articles analysed according to their consistency with the inclusion and exclusion criteria.

Conclusions: Three main aspects emerged from the review: (1) According to the existing literature, new randomized controlled trials are needed to ensure a better understanding of the most effective drug treatments for dual-diagnosed ASD-ADHD patients and of the related behavioural effects. Currently, the use of drugs varies depending on psychiatric comorbidity, symptoms, age and gender and there is no univocal reference therapy; (2) Methylphenidate (MPH) has currently been shown to be the most suitable drug for the treatment of hyperactivity and inattention in individuals diagnosed with ASD and ADHD; (3) There is a need to create and evaluate appropriate tests to analyse more specific patterns of behaviour presented in the two conditions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Negotiating assistive technologies and AI in inclusive education: professional agency in neurodivergent contexts. Perceptions of autism and experiences of stigma among Somali and Eritrean immigrant parents in Norway: a qualitative study. The long-term impact of adverse childhood experiences on externalizing aggressiveness: sensitive periods during childhood and adolescence. Latent trajectories of early social communication development are associated with autism diagnosis and language outcomes. Maternal adverse childhood experiences, postnatal depression, and early parenting behaviors: a study of microcoded mother-infant interaction in early infancy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1